Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604058 | 1.00 | L3MBTL1 (0.32) | L3MBTL1 | |
| Water SCHEMBL1831822 | 0.99 | L3MBTL1 (0.31) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29571133 | 0.99 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL20744587 | 0.75 | — | — | |
| SCHEMBL1833700 | 0.74 | GUCY1B2 (0.32) | L3MBTL1 | |
| SCHEMBL1560736 | 0.74 | GUCY1B2 (0.32) | L3MBTL1 | |
| SCHEMBL20740318 | 0.70 | — | — | |
| SCHEMBL20740317 | 0.70 | — | — | |
| SCHEMBL4554040 | 0.65 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL13372164 | 0.65 | L3MBTL1 (0.32) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | claimed |
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | AC BIOSCIENCE (CH) | 2023-12-26 | — | — | US | disclosed |
| CN-114555567-A | Compounds and their use for the treatment of infectious diseases and cancer | AC生命科学有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | disclosed |
| EP-3668506-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BioScience (CH) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | disclosed |
| CN-102131803-A | Solid forms of (1R,2S,3R) -1- (2- (isoxazol-3-yl) -1H-imidazol-4-yl) butane-1, 2,3, 4-tetraol and methods of use thereof | LEXICON PHARMACEUTICALS INC | 2011-07-20 | — | — | CN | disclosed |
| EP-2315765-A2 | SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010008733-A2 | SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | SPHK1, S1PR1, S1PR2 | L3MBTL1 3874/4885 |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | SPHK1, S1PR1, S1PR2 | L3MBTL1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.